Speed Post News Network
New Delhi : The National Pharmaceutical Pricing Authority (NPPA) on September 29, 2021, condemned the statements regarding its alleged connivance in any malpractices adopted by Pharmaceutical Companies.
National Pharmaceutical Pricing Authority is a regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, Government of India, and is committed to ensure affordability and accessibility of medicine by fixing the ceiling price for scheduled formulations and monitoring the prices of non-scheduled formulations.
The Daily Excelsior, on September 22, 2021, has reported that the Jammu Pharmaceutical Distributors Association (JDPA) has alleged pharmaceutical companies with resorting to corrupt practices by selling most of the medicine at different prices to different sectors despite having same MRP with active connivance of the NPPA.
NPPA strongly condemns such false statements regarding its connivance in any of the malpractices adopted by the pharmaceutical companies. It will be most relevant here to state that NPPA takes action on violation of Ceiling Prices fixed by it for scheduled formulations, Retail Prices fixed by it for New Drugs and increasing MRP of non-scheduled Drugs by more than 10% during the previous 12 months as provided under Para-20 of the Drug Price Control Order (DPCO), 2013, according to a PIB release.
Further, charging different prices below the applicable ceiling price/ MRP to different sectors by pharmaceutical companies is not under the purview of NPPA. It is done purely on commercial terms by the companies which are not under the ambit of the regulatory framework of NPPA.